{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:12:30Z","timestamp":1794244350819,"version":"4.9.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eclinm.2025.103161","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:56:05Z","timestamp":1742957765000},"page":"103161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice"],"prefix":"10.1016","volume":"82","author":[{"given":"Geeta","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Adattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Armstrong Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrinne","family":"Bagnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan V.","family":"Boddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkie","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley-Ann","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Kliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Kurkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Mirkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Routledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Shingleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Siderov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian N.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wichart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103161_bib1","author":"Sandhu"},{"key":"10.1016\/j.eclinm.2025.103161_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103102","article-title":"Aligning kidney function assessment in patients with cancer to global practices in internal medicine","volume":"82","author":"Sandhu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2025.103161_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103101","article-title":"A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function","volume":"82","author":"Sandhu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2025.103161_bib4","author":"Ashley"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103161_bib7","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","author":"Krens","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103161_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00216-4","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update","volume":"24","author":"Giraud","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8 Pt 2","key":"10.1016\/j.eclinm.2025.103161_bib10","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/clinchem\/42.8.1322","article-title":"Concepts in use of high-dose methotrexate therapy","volume":"42","author":"Treon","year":"1996","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","article-title":"Advances in individual prediction of methotrexate toxicity: a review","volume":"146","author":"Schmiegelow","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4155\/ipk-2016-0022","article-title":"Clinical pharmacokinetics of methotrexate in oncology","volume":"2","author":"Lev\u00eaque","year":"2017","journal-title":"Int J Pharmacokinetics"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2005.02513.x","article-title":"Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients","volume":"62","author":"Joerger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103161_bib14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","article-title":"Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients","volume":"84","author":"Kawakatsu","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.kint.2019.12.023","article-title":"How to assess kidney function in oncology patients","volume":"97","author":"Malyszko","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.18773\/austprescr.2019.054","article-title":"How to adjust drug doses in chronic kidney disease","volume":"42","author":"Stefani","year":"2019","journal-title":"Aust Prescr"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","article-title":"Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas","volume":"90","author":"Ferreri","year":"2004","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.16866","article-title":"The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper","volume":"190","author":"McKay","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"Zhu","year":"2009","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103161_bib20","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"2-3","key":"10.1016\/j.eclinm.2025.103161_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0959-8049(05)80126-1","article-title":"Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer","volume":"28","author":"Beex","year":"1992","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103161_bib22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1984.2.12.1404","article-title":"Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance","volume":"2","author":"Gelman","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103161_bib23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1200\/JCO.2015.62.6341","article-title":"Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an Ancillary Study of CALGB\/CTSU 49907","volume":"34","author":"Lichtman","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103161_bib24","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib25","first-page":"15","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J\u00a0Nephrol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103161_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0002-9343(84)90280-8","article-title":"Lack of age-dependent cisplatin nephrotoxicity","volume":"76","author":"Hrushesky","year":"1984","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103161_bib27","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1200\/JCO.1986.4.9.1392","article-title":"Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin","volume":"4","author":"Reece","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/clpt.1986.24","article-title":"Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin","volume":"39","author":"Vermorken","year":"1986","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103161_bib29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jjco\/hyv082","article-title":"Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes","volume":"45","author":"Ichioka","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103161_bib30","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/j.clgc.2018.02.002","article-title":"Feasibility of cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with diminished renal function","volume":"16","author":"Koshkin","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103161_bib31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00000421-198306000-00019","article-title":"Cis-platinum plus high-dose methotrexate. Toxicity and efficacy in ovarian carcinoma","volume":"6","author":"Talley","year":"1983","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103161_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101902","article-title":"Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection","volume":"9","author":"Kidera","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2025.103161_bib33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2147\/TCRM.S165531","article-title":"The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly","volume":"14","author":"Liu","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103161_bib34","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/j.1875-9114.1997.tb03088.x","article-title":"Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors","volume":"17","author":"Lagrange","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103161_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/1060028014533303","article-title":"Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol","volume":"48","author":"Morgan","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103161_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103161_bib37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/clpt.1987.155","article-title":"Disposition of unchanged cisplatin in patients with ovarian cancer","volume":"42","author":"Reece","year":"1987","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103161_bib39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103161_bib40","first-page":"239","article-title":"Chemotherapy with cisplatin, epirubicin, methotrexate in the treatment of locally advanced or metastatic transitional cell cancer of the bladder (TCC)","volume":"4","author":"Lelli","year":"1992","journal-title":"J\u00a0Chemother"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103161_bib41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/j.1552-4604.1988.tb03134.x","article-title":"Clinical pharmacokinetics of carboplatin","volume":"28","author":"Oguri","year":"1988","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103161_bib42","first-page":"1103","article-title":"Phase I clinical and pharmacologic trial of carboplatin daily for 5 days","volume":"68","author":"Van Echo","year":"1984","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00292413","article-title":"Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients","volume":"23","author":"Colombo","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103161_bib44","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103161_bib45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","article-title":"Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer","volume":"10","author":"Jodrell","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.eclinm.2025.103161_bib46","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1200\/JCO.2010.29.3597","article-title":"Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure","volume":"28","author":"Schmitt","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1 Suppl 2","key":"10.1016\/j.eclinm.2025.103161_bib47","first-page":"107","article-title":"Intraperitoneal carboplatin: rationale and experience","volume":"19","author":"Speyer","year":"1992","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0277-5379(88)90262-3","article-title":"Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG)","volume":"24","author":"van Glabbeke","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103161_bib49","series-title":"National Cancer Institute Common Terminology Criteria for Adverse Events: (CTCAE)","year":"2017"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00280-015-2769-9","article-title":"Extension of the Calvert formula to patients with severe renal insufficiency","volume":"76","author":"Oguri","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1186\/s12885-022-09885-7","article-title":"Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice","volume":"22","author":"Akg\u00fcl","year":"2022","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.eclinm.2025.103161_bib52","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib53","first-page":"303","article-title":"A\u00a0formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103161_bib54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ygyno.2020.03.017","article-title":"Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care","volume":"157","author":"McLean","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103161_bib55","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.ajkd.2017.10.005","article-title":"Improving carboplatin dosing based on estimated GFR","volume":"71","author":"Beumer","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1078155220978446","article-title":"Accurate determination of glomerular filtration rate in adults for carboplatin dosing: moving beyond Cockcroft and Gault","volume":"27","author":"Tsang","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.eclinm.2025.103161_bib58","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jppr.1884","article-title":"Estimation of kidney function for medication dosing in adult patients with chronic kidney disease: a practice update","volume":"54","author":"Mirkov","year":"2024","journal-title":"J\u00a0Pharm Pract Res"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103161_bib60","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: a statement from the American society of Onco-nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","article-title":"A\u00a0prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103161_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100771","article-title":"Analyses of nivolumab exposure and clinical safety between 3-mg\/kg dosing and 240-mg flat dosing in Asian patients with advanced renal cell carcinoma in the real-world clinical setting","volume":"13","author":"Kato","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.eclinm.2025.103161_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1623957","article-title":"Efficacy of nivolumab in a patient with metastatic renal cell carcinoma and end-stage renal disease on dialysis: case report and literature review","volume":"2018","author":"Ansari","year":"2018","journal-title":"Case Reports Immunol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103161_bib65","first-page":"244","article-title":"Evaluation of checkpoint inhibitors in cancer patients with end-stage renal disease on hemodialysis: case series and review of the literature","volume":"43","author":"Jain","year":"2020","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.eclinm.2025.103161_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","author":"Kanz","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib67","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/CMR.0000000000000616","article-title":"Are patients in haemodialysis good candidates for immunotherapy treatment?","volume":"29","author":"Fernandez-Diaz","year":"2019","journal-title":"Melanoma Res"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103161_bib68","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"issue":"3-4","key":"10.1016\/j.eclinm.2025.103161_bib69","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000504515","article-title":"Outcomes and safety of biweekly and monthly nivolumab in patients with metastatic renal cell carcinoma and dialysis: three case reports and literature review","volume":"104","author":"Osm\u00e1n-Garc\u00eda","year":"2020","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103161_bib70","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1016\/j.clgc.2019.04.004","article-title":"Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma and end-stage renal disease at 2 centers","volume":"17","author":"Tachibana","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103161_bib71","doi-asserted-by":"crossref","first-page":"e903","DOI":"10.1016\/j.clgc.2019.06.009","article-title":"Immunotherapy in dialysis-dependent cancer patients: our experience in patients with metastatic renal cell carcinoma and a review of the literature","volume":"17","author":"Vitale","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors","volume":"79","author":"Chute","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A\u00a0systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103161_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252978","article-title":"Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study","volume":"16","author":"Koks","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103161_bib76","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103161_bib77","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103161_bib78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"36","key":"10.1016\/j.eclinm.2025.103161_bib79","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103161_bib80","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:42:43Z","timestamp":1786135363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":77,"alternative-id":["S2589537025000938"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103161","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103101","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103102","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103161"}}